Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males

What Was Tested

The paper reports a study of Kisspeptin-10 and Kisspeptin-54, published as a randomized controlled trial.

The present study was designed to determine the effects of elevating circulating kisspeptin levels on LH, FSH, and testosterone in male volunteers.

Why It Was Studied

The endogenous neuropeptide agonist for G protein-coupled receptor 54, kisspeptin, potently stimulates the hypothalamic-pituitary-gonadal axis in rodents and primates.

Who Took Part

By PubMed's age tags, the people studied were adults, men only.

Male volunteers (n = 6) were recruited.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Random assignment meant chance, not the researchers, decided who got Kisspeptin-10 and who got the comparison, which limits bias.

As a double-blind Kisspeptin-10 study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Kisspeptin-10, giving a reference point.

In the crossover set-up each of the participants took both Kisspeptin-10 and the comparison in turn, acting as their own control.

This was a double-blind, placebo-controlled, crossover study.

This was a hospital-based study.

What Was Measured

PubMed files the paper under topics including Follicle Stimulating Hormone, Half-Life, Hypothalamo-Hypophyseal System, Kisspeptins, Luteinizing Hormone, Osmolar Concentration and Pituitary-Adrenal System.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Kisspeptin-10 and Kisspeptin-54.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2005 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Kisspeptin-10 compound page and the Kisspeptin-54 compound page.